Emerging evidence suggests that the recently approved anti-amyloid therapies are most efficacious in amyloid β (Aβ)-positive individuals without a high tau burden. Lyduine Collij, PhD, BioFINDER group, Lund University, Lund, Sweden, shares her research looking into plasma biomarkers as prescreening tools to identify Aβ-positive patients without an advanced stage of tau pathology who are most likely to benefit from anti-amyloid immunotherapies. Over 900 individuals from the BioFINDER-2 cohort were included in the study. Numerous biomarkers were assessed for their ability to classify participants by Aβ and tau status, including p-tau181, p-tau217, p-tau231, GFAP, and NfL. Plasma p-tau217 was the most strongly associated with Aβ-positivity. Using a 2-cut-point procedure, individuals with a high certainty of Aβ-positivity or -negativity were separated from those with ambiguous plasma p-tau217 values, minimizing the need for confirmatory PET scans. When assessing tau load among Aβ-positive participants, p-tau217 was the best performing biomarker for identifying low-intermediate versus high tau-PET. In this way, plasma p-tau217 was shown to efficiently identify Aβ-positive individuals likely to have a low tau load according to tau-PET, minimizing the number of confirmatory Aβ- and tau-PET tests required.
For full study details: https://jamanetwork.com/journals/jamaneurology/article-abstract/2812432
This interview took place at the CTAD 2023 conference in Boston, MA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Dr. Collij has received research support from GE Healthcare and Springer Healthcare (paid by Eli Lilly). Both are paid to instituation. Dr. Collij’s salary is supported by the MSCA Doctoral Fellowship grant (#101108819) and Alzheimer Association Research Fellowship grant (#23AARF-1029663).